@article{3081572,
    title = "A randomized trial of nasal spray salmon calcitonin in men with
idiopathic osteoporosis: Effects on bone mineral density and bone
markers",
    author = "Trovas, GP and Lyritis, GP and Galanos, A and Raptou, P and and Constantelou, E",
    journal = "JOURNAL OF BONE AND MINERAL RESEARCH",
    year = "2002",
    volume = "17",
    number = "3",
    pages = "521-527",
    publisher = "AMER SOC BONE & MINERAL RES",
    issn = "0884-0431",
    doi = "10.1359/jbmr.2002.17.3.521",
    keywords = "calcitonin; osteoporosis in men; bone densitometry; bone markers; bone
turnover",
    abstract = "In a 12-month randomized, double-blind, placebo-controlled trial, we
have studied the effects of intranasal salmon calcitonin (SCT) on bone
mineral density (BMD) and biochemical markers of bone turnover.
Twenty-eight men with idiopathic osteoporosis aged 27-74 years (mean,
52.4 years) were randomized to receive either nasal SCT (200 IU) or a
nasal placebo daily for a period of 1 year. All the men received a daily
supplement of 0.5 g of calcium. The men who received SCT had a mean
(+/-SEM) increase in BMD of 7.1 +/- 1.7% at the lumbar spine. In
contrast, the men who received the placebo had an increase of 2.4 +/-
1.5% (p > 0.05) for the comparison with baseline. The increase in
lumbar BMD in the calcitonin group was significantly greater than that
in the placebo group (p < 0.05). There were no significant changes in
the femoral neck, trochanter, or Ward’s triangle relative to both
baseline and placebo after 12 months. Treatment with nasal SCT resulted
in a significantly pronounced suppression of bone resorption markers
(urinary deoxypyridinoline [DPD], type I cross-linked N-telopeptide
[NTX], and type I cross-linked C-telopeptide [CTX]) and to a lesser
extent in bone formation markers (serum bone-specific alkaline
phosphatase [BALP], osteocalcin [OC], serum C-terminal procollagen
type I extension peptides [PICP], and serum N-terminal procollagen
type I extension peptides [PINP]), whereas the placebo did not.
Therapy was tolerated well and there were no treatment-related adverse
events. We conclude that intranasal SCT (200 IU daily) is safe and
effective in increasing lumbar BMD and reducing bone turnover in men
with idiopathic osteoporosis."
}